Biomedical Nanotethering
A nanoparticle platform designed to carry a range of therapeutic payloads and tether them precisely where the body needs them.
Platform Advantage
Cargo on the outside
Bioactive cargos attach to the nanoparticle surface simply by mixing them together in water.
The nanoparticles tether the cargo to a device or to the tissue being treated, so a precise dose can do more where it matters.
A shared core platform can be used for many applications because there's no new linking chemistry to develop for each cargo.
Peripheral Artery Treatment
Helping blood vessels heal more naturally after treatment for peripheral artery disease
Explore the program →
Heart Valve Treatment
Helping bioprosthetic heart valves last longer by protecting their leaflets from the earliest triggers of failure
Explore the program →Leadership & Team
The people building Nanomedx
Leadership
Bede O'Connor
CEO & Director
Prof. Steven Wise
CSO & Director
Co-Founder
Jeff Reid
Investor & Director
Team
Dr. Richard Tan
Head of Cardiovascular Programs
Co-Founder
Chien Hung
Biological Scientist
Co-Founder
Dr. Timothy Mitchell
Lead Engineer
Danyon Munro
Regulatory & Quality Manager
Technology
First use of plasma to create and capture nanoparticles for biomedical applications
Plasma processes have driven semiconductors and advanced coatings for decades.
Nanomedx was the first to capture plasma nanoparticles for biomedical use.
Nanomedx has now developed unique advanced manufacturing capability for production of plasma polymerised nanoparticles.
Plasma-synthesized nanocarriers
Carbon nanoparticles synthesised by plasma polymerisation, binding bioactive cargo directly to the particle surface without chemical linkers.
Advanced Manufacturing
A dry, single-step synthesis process avoids multi-step formulation and purification. Production runs on apparatus designed and patented in-house, engineered to scale from lab synthesis toward GMP-grade output.
Peer-reviewed safety data
Built from carbon and nitrogen rather than synthetic lipids or metals. Toxicity and biosafety have been characterised in peer-reviewed studies, and the platform has delivered growth factors, dual siRNA and biologic cargo in vivo.
Protected by six patent families
IP spans the core nanoparticle platform, the manufacturing process, biologic conjugation chemistry, and application-specific delivery devices.
Interested in the Nanomedx platform?
Get in touch to discuss partnership, licensing, or investment opportunities.